{"key":"op_790_KR","page":{"url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=target-therapy-for-lung-cancer/","procedure":{"id":790,"slug":"target-therapy-for-lung-cancer","name":"Таргетна терапія при раку легень","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":36,"iso":"KR","name":"Південна Корея"},"currency":"USD","data_date":"2026-09-24"},"pages":{"clinics_url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=target-therapy-for-lung-cancer/","cost_url":"https://ua.bookimed.com/clinics/country=republic-of-korea/procedure=target-therapy-for-lung-cancer/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":2500,"to":15000,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":90000,"to":150000},"uk":{"from":14000,"to":25000},"by_technique":{"status":"missing","reason":"not_collected"},"by_city":[{"city":"Сеул","from":2500}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":3500,"to":7000},{"country_iso":"FR","from":6500,"to":13000},{"country_iso":"GB","from":14000,"to":25000},{"country_iso":"US","from":90000,"to":150000},{"country_iso":"IL","from":9000,"to":16000},{"country_iso":"TR","from":5000,"to":5800},{"country_iso":"MX","from":6500,"to":12000},{"country_iso":"DE","from":3000,"to":27000},{"country_iso":"CA","from":9000,"to":20000},{"country_iso":"AE","from":9000,"to":14000},{"country_iso":"TH","from":9000,"to":13500},{"country_iso":"PL","from":4500,"to":8500},{"country_iso":"CZ","from":4500,"to":9000},{"country_iso":"AT","from":9000,"to":18000},{"country_iso":"ES","from":4500,"to":13000},{"country_iso":"IT","from":8200,"to":15900},{"country_iso":"CN","from":1600,"to":13000},{"country_iso":"AU","from":3800,"to":7500},{"country_iso":"IN","from":1000,"to":5500},{"country_iso":"MY","from":1800,"to":5400},{"country_iso":"VN","from":5000,"to":9500},{"country_iso":"BR","from":4500,"to":7000}],"base_country":"US","base_is_fallback":false},"savings":{"pct":97,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":5,"items":[{"id":262,"name":"Samsung Medical Center","city":"Seoul","rating":4.5,"reviews_count":25,"accreditations":["International Organization for Standardization","Korean Institute for Healthcare Accreditation","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Largest cancer center in Asia with a dedicated lung cancer department. Over 50,000 cancer patients treated. Clinical trials at in-house institute provide access to novel targeted therapies.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":8459,"name":"Myongji Hospital","city":"Goyang","rating":3.6,"reviews_count":{"status":"missing","reason":"not_collected"},"accreditations":["Advanced Regenerative Medicine Implementation Institution (Ministry of Health and Welfare, Republic of Korea)"],"rank":2,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":408,"name":"Seoul National University Bundang Hospital (SNUBH)","city":"Seoul","rating":4.9,"reviews_count":7,"accreditations":["Global Healthcare Accreditation Program","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":3,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":254,"name":"Severance Hospital","city":"Seoul","rating":4.5,"reviews_count":43,"accreditations":["Joint Commission International","Korean Institute for Healthcare Accreditation","World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":4,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}},{"id":421,"name":"Seoul National University Hospital (SNUH)","city":"Seoul","rating":5,"reviews_count":1,"accreditations":["World's Best Hospitals 2021 by Newsweek","World's Best Smart Hospitals 2021 by Newsweek","World's Best Hospitals 2022 by Newsweek","World's Best Smart Hospitals 2023 by Newsweek"],"rank":5,"has_procedure":true,"why_ranked":{"status":"missing","reason":"not_collected"},"bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":{"status":"missing","reason":"not_collected"},"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":328,"slug":"seoul","name":"Сеул","clinics_count":1,"price_from":2500,"profile":{"city_type":"Capital of Republic of Korea","access":["Incheon Airport (ICN), 48 km west of Seoul","Gimpo Airport (GMP), 15 km west of central Seoul"],"sources":["https://en.wikipedia.org/wiki/Seoul","https://en.wikipedia.org/wiki/Incheon_International_Airport","https://en.wikipedia.org/wiki/Gimpo_International_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Advanced or metastatic NSCLC with EGFR exon 19 deletion","Advanced or metastatic NSCLC with EGFR L858R mutation","Adjuvant therapy after resection of EGFR-mutated NSCLC","Unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy"],"contraindications":["Severe hypersensitivity to osimertinib or its components.","Current interstitial lung disease or pneumonitis.","Congenital long QT syndrome or uncorrectable electrolyte disturbances.","Clinically significant cardiomyopathy or reduced ventricular function.","Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort).","Pregnancy or planned conception (not recommended)."],"operation_hours":{"min":0.5,"max":3,"unit":"hours","qualifier":"Initial clinic visit for counseling and start; daily tablet takes minutes and therapy continues until progression."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":4,"max":8,"unit":"visits","qualifier":"Planned oncology reviews in the first 6 months from treatment start."},"stages":[{"code":"baseline_start","label":"Baseline assessment, counseling and start of daily oral therapy","after":{"min":0,"max":0,"unit":"days","qualifier":"Counted from treatment start."}},{"code":"early_tolerability_review","label":"Tolerability and laboratory review","after":{"min":14,"max":28,"unit":"days","qualifier":"After the first dose."}},{"code":"first_response_assessment","label":"First response imaging and clinic review","after":{"min":42,"max":84,"unit":"days","qualifier":"After the first dose; timing varies by clinic."}},{"code":"ongoing_scheduled_reviews","label":"Ongoing reviews with periodic imaging every 2 to 3 months","after":{"min":84,"max":180,"unit":"days","qualifier":"After the first dose; later intervals individualized."}}],"qualifier":"Daily oral osimertinib after biomarker confirmation, continued until progression or intolerance. Counts cover first 6 months only."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Oral therapy taken at home; no hospital stay in an uncomplicated course. Infusion-based regimens are outside this profile."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":7,"unit":"days","qualifier":"Oral therapy without procedure; time to settle into daily routine, affected by rash, diarrhea, fatigue and disease burden."},"fly_home_after_days":{"min":0,"max":14,"unit":"days","qualifier":"No procedure; travel is possible after baseline workup, once stable with enough medication. Tolerability review at about 2–4 weeks."},"back_to_work_days":{"min":0,"max":7,"unit":"days","qualifier":"No procedure or stay; many patients with good performance status work within a week, adjusted for side effects."},"exercise_resume_weeks":{"min":0,"max":2,"unit":"weeks","qualifier":"Light activity from day 1; strenuous exercise gradually over 1 to 2 weeks if tolerability and breathing allow."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Time to first radiologic response assessment, about 6 to 12 weeks. Not a cure endpoint; therapy continues."},"result_longevity":"Disease control typically lasts months to a few years until resistance develops; median first-line progression-free survival was roughly 1.5 years. Benefit lasts only during therapy; not a cure.","main_risks":["Diarrhea, dry skin, rash, paronychia, mouth sores; usually manageable.","Interstitial lung disease: rare but serious; stop drug, urgent evaluation.","QT prolongation; rarely reduced heart function.","Low blood counts and liver enzyme changes found on monitoring.","Eye symptoms and rare severe skin reactions.","Drug interactions, especially with CYP3A4 inducers."],"complication_rate_pct":{"min":1,"max":5,"unit":"percent","qualifier":"Approximate rate of interstitial lung disease or pneumonitis on osimertinib; milder effects like rash and diarrhea are far more common."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Objective response rate (tumor shrinkage on imaging)","value":80,"horizon":"First response imaging, about 6 to 12 weeks after first dose","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"None; no incisions.","pain":"Taking the oral tablet is painless. Treatment-related discomfort, such as mouth sores, nail-fold tenderness, rash or headache, can occur and is managed symptomatically.","preparation":["Confirm NSCLC and EGFR mutation by tissue or liquid biopsy","Baseline staging, usually CT with brain imaging, per the oncologist.","Baseline blood counts, liver and kidney tests, electrolytes","ECG and cardiac assessment as indicated","Review all medicines and supplements for CYP3A4 and QT interactions.","Counseling on side effects, dosing, skin and nail care","Contraception advice and when to contact the oncology team"],"recovery_timeline":[{"phase":"Treatment start (day 0)","description":"Baseline assessment and counseling, then daily oral osimertinib starts at home. No hospital stay; light activity continues from day 1.","restrictions":["Take the tablet daily as directed","Avoid interacting drugs and supplements unless cleared","Use contraception as advised"]},{"phase":"Days 1 to 28","description":"Mild diarrhea, dry skin, rash, nail changes, mouth sores and fatigue may appear; supportive care helps. Exercise resumes gradually.","restrictions":["Daily skin, nail and mouth care","Maintain hydration","Increase exercise gradually, guided by oncology team"]},{"phase":"Weeks 6 to 12","description":"First response imaging and clinic review; initial response is judged and monitoring continues.","restrictions":["Continue treatment unless the oncology team advises otherwise"]},{"phase":"Ongoing therapy (months 3 to 6 and beyond)","description":"Daily therapy with periodic reviews and imaging until progression or intolerance; repeat testing if disease progresses.","restrictions":["Continue regular monitoring as scheduled","Do not stop or change dose without oncology advice"]},{"phase":"At any time","description":"Seek urgent care for new cough, breathlessness, fever, chest pain, palpitations, severe diarrhea, severe rash, eye pain, or infection or bleeding signs.","restrictions":["Do not wait for the next review","Team may pause the drug during assessment"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":14,"max":28,"unit":"days","qualifier":"After the first dose; tolerability and laboratory review."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"After the first dose; first response imaging and clinic review."}},{"purpose":"assessment","requirement":"routine","after":{"min":84,"max":180,"unit":"days","qualifier":"After the first dose; periodic imaging every 2 to 3 months, later intervals individualized."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the doctor explains the risks of any biopsy needed for the tumor before it is done","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Your doctor will explain the risks of having a biopsy for your type of tumor.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C2","text":"Check whether the doctor explains that cancer cells can become resistant to targeted therapy","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Cancer cells can become resistant to targeted therapy.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C3","text":"Check the plan for regular visits, blood tests and scans, which show whether the treatment is working","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"These regular visits and tests will help the doctor know whether the treatment is working.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C4","text":"Check that the side effects of the specific targeted drug you would receive are explained before treatment starts","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"The side effects that you may have depends on the type of targeted therapy you receive and how your body reacts to it.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C5","text":"Check that your tumor has been tested for drug targets, which is needed most of the time","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Promise that the doctor can know for certain how you will feel during treatment","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Doctors and nurses cannot know for certain how you will feel during treatment.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"F2","text":"Ad or quote calling targeted therapy free of serious side effects","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But they have learned that targeted therapy can also cause serious side effects.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"F3","text":"Targeted therapy offered without any mention of testing the tumor for drug targets","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"warning_signs":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-14","next_check_at":"2027-02-12"},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":7,"unit":"days","qualifier":"No procedure or stay; many patients with good performance status work within a week, adjusted for side effects."},"complication_rate_pct":{"min":1,"max":5,"unit":"percent","qualifier":"Approximate rate of interstitial lung disease or pneumonitis on osimertinib; milder effects like rash and diarrhea are far more common."},"contraindications":["Severe hypersensitivity to osimertinib or its components.","Current interstitial lung disease or pneumonitis.","Congenital long QT syndrome or uncorrectable electrolyte disturbances.","Clinically significant cardiomyopathy or reduced ventricular function.","Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St John's wort).","Pregnancy or planned conception (not recommended)."],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Oral therapy taken at home; no hospital stay in an uncomplicated course. Infusion-based regimens are outside this profile."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":2,"unit":"weeks","qualifier":"Light activity from day 1; strenuous exercise gradually over 1 to 2 weeks if tolerability and breathing allow."},"final_result_months":{"min":1,"max":3,"unit":"months","qualifier":"Time to first radiologic response assessment, about 6 to 12 weeks. Not a cure endpoint; therapy continues."},"fly_home_after_days":{"min":0,"max":14,"unit":"days","qualifier":"No procedure; travel is possible after baseline workup, once stable with enough medication. Tolerability review at about 2–4 weeks."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":14,"max":28,"unit":"days","qualifier":"After the first dose; tolerability and laboratory review."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"After the first dose; first response imaging and clinic review."}},{"purpose":"assessment","requirement":"routine","after":{"min":84,"max":180,"unit":"days","qualifier":"After the first dose; periodic imaging every 2 to 3 months, later intervals individualized."}}],"indications":["Advanced or metastatic NSCLC with EGFR exon 19 deletion","Advanced or metastatic NSCLC with EGFR L858R mutation","Adjuvant therapy after resection of EGFR-mutated NSCLC","Unresectable stage III EGFR-mutated NSCLC after chemoradiotherapy"],"main_risks":["Diarrhea, dry skin, rash, paronychia, mouth sores; usually manageable.","Interstitial lung disease: rare but serious; stop drug, urgent evaluation.","QT prolongation; rarely reduced heart function.","Low blood counts and liver enzyme changes found on monitoring.","Eye symptoms and rare severe skin reactions.","Drug interactions, especially with CYP3A4 inducers."],"pain":"Taking the oral tablet is painless. Treatment-related discomfort, such as mouth sores, nail-fold tenderness, rash or headache, can occur and is managed symptomatically.","preparation":["Confirm NSCLC and EGFR mutation by tissue or liquid biopsy","Baseline staging, usually CT with brain imaging, per the oncologist.","Baseline blood counts, liver and kidney tests, electrolytes","ECG and cardiac assessment as indicated","Review all medicines and supplements for CYP3A4 and QT interactions.","Counseling on side effects, dosing, skin and nail care","Contraception advice and when to contact the oncology team"],"recovery_timeline":[{"phase":"Treatment start (day 0)","description":"Baseline assessment and counseling, then daily oral osimertinib starts at home. No hospital stay; light activity continues from day 1.","restrictions":["Take the tablet daily as directed","Avoid interacting drugs and supplements unless cleared","Use contraception as advised"]},{"phase":"Days 1 to 28","description":"Mild diarrhea, dry skin, rash, nail changes, mouth sores and fatigue may appear; supportive care helps. Exercise resumes gradually.","restrictions":["Daily skin, nail and mouth care","Maintain hydration","Increase exercise gradually, guided by oncology team"]},{"phase":"Weeks 6 to 12","description":"First response imaging and clinic review; initial response is judged and monitoring continues.","restrictions":["Continue treatment unless the oncology team advises otherwise"]},{"phase":"Ongoing therapy (months 3 to 6 and beyond)","description":"Daily therapy with periodic reviews and imaging until progression or intolerance; repeat testing if disease progresses.","restrictions":["Continue regular monitoring as scheduled","Do not stop or change dose without oncology advice"]},{"phase":"At any time","description":"Seek urgent care for new cough, breathlessness, fever, chest pain, palpitations, severe diarrhea, severe rash, eye pain, or infection or bleeding signs.","restrictions":["Do not wait for the next review","Team may pause the drug during assessment"]}],"rehabilitation_days":{"min":0,"max":7,"unit":"days","qualifier":"Oral therapy without procedure; time to settle into daily routine, affected by rash, diarrhea, fatigue and disease burden."},"result_longevity":"Disease control typically lasts months to a few years until resistance develops; median first-line progression-free survival was roughly 1.5 years. Benefit lasts only during therapy; not a cure.","revision_rate_pct":null,"scars":"None; no incisions.","sessions_or_stages":{"sessions":{"min":4,"max":8,"unit":"visits","qualifier":"Planned oncology reviews in the first 6 months from treatment start."},"stages":[{"code":"baseline_start","label":"Baseline assessment, counseling and start of daily oral therapy","after":{"min":0,"max":0,"unit":"days","qualifier":"Counted from treatment start."}},{"code":"early_tolerability_review","label":"Tolerability and laboratory review","after":{"min":14,"max":28,"unit":"days","qualifier":"After the first dose."}},{"code":"first_response_assessment","label":"First response imaging and clinic review","after":{"min":42,"max":84,"unit":"days","qualifier":"After the first dose; timing varies by clinic."}},{"code":"ongoing_scheduled_reviews","label":"Ongoing reviews with periodic imaging every 2 to 3 months","after":{"min":84,"max":180,"unit":"days","qualifier":"After the first dose; later intervals individualized."}}],"qualifier":"Daily oral osimertinib after biomarker confirmation, continued until progression or intolerance. Counts cover first 6 months only."},"success":{"metric":"Objective response rate (tumor shrinkage on imaging)","value":80,"unit":"percent","horizon":"First response imaging, about 6 to 12 weeks after first dose","population":"Adults with advanced EGFR exon 19 or L858R NSCLC on first-line osimertinib","evidence_status":"limited"},"techniques":[{"name":"Oral EGFR tyrosine kinase inhibitor (osimertinib)","suits_whom":"Adults with EGFR-mutated advanced NSCLC.","recovery":"Taken at home daily; no procedural recovery, with side-effect management and monitoring as directed."},{"name":"Other oral targeted inhibitors (ALK, ROS1, RET, MET, BRAF/MEK, KRAS G12C, HER2)","suits_whom":"Patients with the matching actionable alteration; the choice follows biomarker results and approvals.","recovery":"Taken at home as continuous therapy; monitoring and side effects are agent-specific."},{"name":"Antibody-based targeted regimens, such as EGFR-MET bispecific antibody or antibody-drug conjugates","suits_whom":"Selected patients with specific alterations or after progression on oral inhibitors; availability varies.","recovery":"Given by intravenous infusion in a treatment unit; schedules and observation are product-specific."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":3,"unit":"hours","qualifier":"Initial clinic visit for counseling and start; daily tablet takes minutes and therapy continues until progression."},"initial_assessment_documents":["Lung biopsy pathology report","EGFR and other biomarker test report (NGS)","Chest CT or PET-CT report and images","Brain MRI report","Recent blood tests with liver and kidney function","Previous cancer treatment summary (if available)"],"travel_trips":{"min":1,"max":3,"one_trip_possible":true,"qualifier":"Daily oral therapy; one 1-2 week trip covers workup and start; imaging and reviews may need return trips."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the doctor explains the risks of any biopsy needed for the tumor before it is done","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Your doctor will explain the risks of having a biopsy for your type of tumor.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C2","text":"Check whether the doctor explains that cancer cells can become resistant to targeted therapy","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Cancer cells can become resistant to targeted therapy.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C3","text":"Check the plan for regular visits, blood tests and scans, which show whether the treatment is working","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"These regular visits and tests will help the doctor know whether the treatment is working.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C4","text":"Check that the side effects of the specific targeted drug you would receive are explained before treatment starts","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"The side effects that you may have depends on the type of targeted therapy you receive and how your body reacts to it.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"C5","text":"Check that your tumor has been tested for drug targets, which is needed most of the time","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"Promise that the doctor can know for certain how you will feel during treatment","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"Doctors and nurses cannot know for certain how you will feel during treatment.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"F2","text":"Ad or quote calling targeted therapy free of serious side effects","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But they have learned that targeted therapy can also cause serious side effects.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},{"id":"F3","text":"Targeted therapy offered without any mention of testing the tumor for drug targets","scope":"treatment_type","source":{"url":"https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies","host":"cancer.gov","quote":"But most of the time, your tumor will need to be tested to see if it contains targets for which there is a drug.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"warning_signs":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-14","next_check_at":"2027-02-12"},"take_home":{"status":"ok","items":[{"id":"T1","text":"Home doctor needs the clinic's follow-up recommendations in a written discharge summary","document":"discharge summary","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"When you have treatment abroad, you must ask the treatment provider for their follow-up recommendations documented within a written discharge summary in English.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your lung cancer can be removed with surgery","name":"Lung cancer surgery","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"You may have surgery to remove cancer from your lung.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200},"operation_id":374}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"technique_details":{"status":"ok","items":[{"id":"oral-egfr-tyrosine","name":"Oral EGFR tyrosine kinase inhibitor (osimertinib)","how_it_works":{"text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"other-oral-targeted","name":"Other oral targeted inhibitors (ALK, ROS1, RET, MET, BRAF/MEK, KRAS G12C, HER2)","how_it_works":{"text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"antibody-based-targeted","name":"Antibody-based targeted regimens, such as EGFR-MET bispecific antibody or antibody-drug conjugates","how_it_works":{"text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1}}},"techniques":[{"id":"oral-egfr-tyrosine","name":"Oral EGFR tyrosine kinase inhibitor (osimertinib)","how_it_works":{"id":"H1","text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Adults with EGFR-mutated advanced NSCLC.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Taken at home daily; no procedural recovery, with side-effect management and monitoring as directed."},{"id":"other-oral-targeted","name":"Other oral targeted inhibitors (ALK, ROS1, RET, MET, BRAF/MEK, KRAS G12C, HER2)","how_it_works":{"id":"H1","text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients with the matching actionable alteration; the choice follows biomarker results and approvals.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Taken at home as continuous therapy; monitoring and side effects are agent-specific."},{"id":"antibody-based-targeted","name":"Antibody-based targeted regimens, such as EGFR-MET bispecific antibody or antibody-drug conjugates","how_it_works":{"id":"H1","text":"Targeted medicines kill cancer cells or stop them growing","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"Targeted medicines kill cancer cells or stop them growing as quickly.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Selected patients with specific alterations or after progression on oral inhibitors; availability varies.","price_from":{"status":"missing","reason":"not_collected"},"recovery":"Given by intravenous infusion in a treatment unit; schedules and observation are product-specific."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your lung cancer can be removed with surgery","name":"Lung cancer surgery","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment/","host":"nhs.uk","quote":"You may have surgery to remove cancer from your lung.","tier":"tier1_medical","fetched_at":"2026-11-14","http_status":200},"operation_id":374}],"checked_at":"2026-11-14","next_check_at":"2027-11-14","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"ok","items":[{"id":"Y1","text":"Republic of Korea runs a medical call center where consultants advise overseas patients in several languages around the clock","specialties":[],"source":{"url":"https://www.khidi.or.kr/board?menuId=MENU00807","host":"khidi.or.kr","quote":"Professional consultants provide advices in Korean, English, Japanese, Chinese, Russian and Arabic 24 hours daily.","tier":"government","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2027-05-10","version":1},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK travelers can enter Republic of Korea for up to 90 days for short-term business or tourism","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"You can enter South Korea for up to 90 days for short-term business or tourism.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"US passport holders need a visa for stays in Republic of Korea longer than 90 days and for purposes other than tourism or business, including employment","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"Visa required for all other purposes, including employment, teaching English, and for stays longer than 90 days.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"For a tourist stay of up to 90 days in Republic of Korea, the passport must expire after the date you leave","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/entry-requirements","host":"gov.uk","quote":"To enter South Korea as a tourist for up to 90 days, your passport must have an ‘expiry date’ after the date you are leaving South Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A valid U.S. passport is required to enter Republic of Korea","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"You must have a valid U.S. passport to enter Korea.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Republic of Korea customs allow small amounts of medication for personal use, if kept in carry-on baggage","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"South Korean customs authorities allow you to bring small amounts of medication for your personal use, if it is kept in carry-on baggage.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V6","item":"hospital_payment","audience":"all","volatile":false,"text":"In Republic of Korea, health care providers usually require payment before treatment or will not release a patient until hospital bills are paid","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/SouthKorea.html","host":"travel.state.gov","quote":"In most cases, health care providers will require payment in advance of treatment or will not release a patient until hospital bills are paid.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V7","item":"emergency_number","audience":"all","volatile":false,"text":"In Republic of Korea, call 119 and ask for an ambulance","source":{"url":"https://www.gov.uk/foreign-travel-advice/south-korea/health","host":"gov.uk","quote":"Call 119 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["china","egypt","germany","india","spain","switzerland","thailand","turkey","ukraine"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.54,"count":76,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p>Target therapy for lung cancer in the Republic of Korea typically costs from _op_790_price_from_ to _op_790_price_to_. The total expense depends on the specific genetic mutation profile, hospital tier, and drug generation. In the US, this procedure costs _price_compare_US_average_ on average. Fees usually cover medical consultations, specific targeted medications, and initial tracking tests.</p>\n\n<ul>\n<li><strong>Hospital tier.</strong> Premier academic centers in Seoul often price services higher than regional hospitals.</li>\n<li><strong>Genetic mutation profile.</strong> Costs vary significantly based on required inhibitors for EGFR, ALK, or ROS1 mutations.</li>\n<li><strong>Diagnostic workup.</strong> Next-generation sequencing tests to identify mutations are usually billed separately.</li>\n<li><strong>Medical hub.</strong> Most advanced oncology centers are located in Seoul and Goyang.</li>\n</ul>\n\n<p><strong>Bookimed Expert Insight.</strong> Major centers like Samsung Medical Center and Severance Hospital provide international-standard care. Samsung Medical Center typically offers oncology services starting around $2,500. Severance Hospital is JCI-accredited and collaborates with top US institutions like MD Anderson. Seoul National University Hospital maintains high cancer survival rates that exceed many US averages. Patients can access proton beam therapy and digital safety systems in these leading facilities.</p>","faq":[{"q":"Are there targeted options for patients without common mutations?","a":"<p>Patients without common lung cancer mutations find several targeted options in South Korea through expanded biomarker testing. South Korean oncology centers use comprehensive genomic profiling to identify rare alterations like RET fusions, KRAS G12C, and NTRK fusions. This precision approach allows for specific therapies even when standard EGFR or ALK tests return negative results.</p> <ul> <li><strong>Genomic profiling:</strong> Next-generation sequencing (NGS) screens 500+ genes to find rare, actionable targets.</li> <li><strong>Specific inhibitors:</strong> Drugs like sotorasib target KRAS G12C and selpercatinib addresses RET fusions.</li> <li><strong>Agnostic therapy:</strong> NTRK inhibitors like larotrectinib work regardless of the primary cancer type.</li> <li><strong>Clinical access:</strong> Major Seoul centers provide early access to new drugs through compassionate use.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from top-tier facilities like Samsung Medical Center and Severance Hospital shows a significant shift toward digital pathology. These institutions use AI-driven systems to analyze biopsy samples faster than traditional manual methods. My advice is to request FoundationOne CDx testing early. While Korean doctors are highly efficient, standard pathways sometimes prioritize basic panels. Asking for comprehensive testing immediately can save weeks in identifying rare, treatable mutations.</p> <p><strong>Patient Consensus:</strong> Many patients find that immunotherapy combinations serve as an effective default when no mutations exist. They emphasize the importance of early PD-L1 testing to ensure these treatments work safely and effectively.</p>"},{"q":"Which targeted drugs are officially approved for lung cancer in South Korea?","a":"<p>The South Korean Ministry of Food and Drug Safety officially approves targeted therapies for lung cancer based on genetic mutations. Key approved drugs include EGFR inhibitors like Osimertinib and Lazertinib, ALK inhibitors such as Alectinib, and breakthrough treatments for ROS1, KRAS, and MET mutations.</p> <ul> <li><strong>EGFR treatments:</strong> South Korea approves 3rd-generation inhibitors like Osimertinib and the domestically developed Lazertinib.</li> <li><strong>ALK inhibitors:</strong> Alectinib, Brigatinib, and Ensartinib are standard-of-care options for ALK-positive lung cancer.</li> <li><strong>Newer targets:</strong> Sotorasib for KRAS G12C and Tepotinib for MET Exon 14 skipping are approved.</li> <li><strong>Immunotherapy:</strong> Keytruda, Opdivo, and Tecentriq are approved based on specific PD-L1 expression levels.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Samsung Medical Center and Severance Hospital offer high success by utilizing Next-Generation Sequencing. This advanced testing is essential because many targeted drugs only receive insurance coverage after specific genetic confirmation. Patients at these top-tier Seoul facilities often bypass the testing delays common in smaller regional clinics.</p> <p><strong>Patient Consensus:</strong> Patients emphasize getting comprehensive genetic testing early at major Seoul centers to unlock insurance-covered drugs. While some experience initial bureaucratic appeals for newer medications, most find the high-tech hospital infrastructure significantly speeds up treatment access.</p>"},{"q":"What are the common side effects of South-Korea-approved targeted therapies?","a":"<p>South-Korea-approved targeted therapies commonly cause dermatological reactions, gastrointestinal distress, and systemic fatigue. Most patients experience acne-like rashes, dry skin, or diarrhea depending on the specific drug mechanism. Korean oncology centers like Samsung Medical Center and Severance Hospital monitor these effects via the Korea Adverse Event Reporting System (KAERS).</p> <ul> <li><strong>Dermatological toxicity:</strong> Acne-like rashes often appear on the face and chest from EGFR inhibitors.</li> <li><strong>Gastrointestinal issues:</strong> Diarrhea and nausea are frequent, though manageable through dietary planning and medication.</li> <li><strong>Systemic fatigue:</strong> Persistent exhaustion affects up to 70% of patients during prolonged clinical treatment.</li> <li><strong>Organ monitoring:</strong> Regular blood work tracks liver enzyme elevation and potential hematological changes.</li> <li><strong>Cardiovascular effects:</strong> High blood pressure is a hallmark side effect for VEGF inhibitor treatments.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Data from top Seoul clinics shows a shift toward second-generation drugs to improve tolerance. Clinics like Seoul National University Hospital use digital tracking to catch side effects early. Dose reductions of 25–50% often stabilize patients without losing treatment efficacy when managed proactively. Most side effects peak early but improve after 4–8 weeks as the body adjusts.</p> <p><strong>Patient Consensus:</strong> Diarrhea is the most persistent daily challenge, often appearing within the first few days. Patients suggest using meal reminders and artificial tears to manage appetite loss and dry eyes effectively.</p>"},{"q":"Which hospitals are internationally recognized for targeted lung-cancer therapy in South Korea?","a":"<p>Samsung Medical Center, Asan Medical Center, and Seoul National University Hospital are internationally recognized leaders for targeted lung cancer therapy in South Korea. These institutions consistently rank among the top ten oncology centers globally, offering advanced molecular testing and access to the latest EGFR, ALK, and ROS1 inhibitors.</p> <ul> <li><strong>Samsung Medical Center:</strong> Ranked 3rd globally for oncology with 63.6% five-year lung cancer survival rates.</li> <li><strong>Asan Medical Center:</strong> Korea largest multidisciplinary hospital leading clinical trials for rare ROS1 and RET mutations.</li> <li><strong>Severance Hospital:</strong> JCI-accredited facility using molecular pathology for customized chemotherapy and targeted drug combinations.</li> <li><strong>Digital infrastructure:</strong> Seoul National University Hospital uses BESTcare systems to enhance patient safety during treatment.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While Samsung and Asan receive the most international acclaim, Severance Hospital manages a massive volume of 4,000,000 outpatients annually. This high turnover has led to one of the most efficient international departments in Seoul. Patients often find faster coordination for genetic testing there than at larger, more research-focused state institutions.</p> <p><strong>Patient Consensus:</strong> Patients value the rapid access to new drug therapies and suggest completing genetic mutation testing before arrival. Many recommend using international departments to navigate the busy hospital wings and ensure clear communication with English-speaking staff.</p>"},{"q":"Is targeted therapy used for never-smokers in South Korea?","a":"thought <p>Targeted therapy is the clinical standard for never-smokers with lung cancer in South Korea. Approximately 70% of never-smokers in Korea qualify for these treatments due to high rates of actionable genetic mutations like EGFR, which appears in up to 63% of this population.</p> <ul> <li><strong>Genetic testing:</strong> Next-generation sequencing (NGS) is mandatory for identifying EGFR, ALK, and ROS1 mutations.</li> <li><strong>First-line treatment:</strong> Surgeons at Samsung Medical Center often prioritize tyrosine kinase inhibitors (TKIs) for adenocarcinoma.</li> <li><strong>Coverage and access:</strong> National insurance covers 50% of NGS costs to ensure rapid treatment starts.</li> <li><strong>Survival outcomes:</strong> Advanced targeted protocols have nearly doubled five-year lung cancer survival rates in Korea.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While many global centers wait for tissue biopsies, top Seoul hospitals like Severance and SNUH utilize rapid liquid biopsy monitoring. Patients can switch to next-generation drugs like osimertinib immediately if resistance mutations like T790M are detected during 6-month checkups.</p> <p><strong>Patient Consensus:</strong> Never-smokers emphasize the importance of requesting immediate genetic screening. Many report that Accessing high-cost drugs like Tagrisso is significantly faster and more affordable through Korea's integrated hospital insurance programs.</p>"}],"h2":[{"text":"Яка вартість таргетної терапії при раку легень в Південній Кореї?","kind":"content"},{"text":"Переваги та гарантії Bookimed","kind":"content"},{"text":"Ваш особистий лікар-координатор Bookimed","kind":"content"},{"text":"Дізнайтеся про найкращі клініки з таргетної терапії при раку легень у Південній Кореї: 5 перевірених клінік та ціни","kind":"content"},{"text":"Огляд процедури Таргетна терапія при раку легень в Південній Кореї","kind":"content"},{"text":"Отримайте медичну консультацію щодо таргетної терапії при раку легень в Південній Кореї: Обирайте серед найкращих фахівців у галузі","kind":"content"},{"text":"Відеоісторії пацієнтів Bookimed","kind":"content"},{"text":"Відгуки про Bookimed: дізнайтеся про реальний досвід пацієнтів","kind":"content"},{"text":"Корисні статті","kind":"content"},{"text":"Поділитися цим контентом","kind":"content"},{"text":"FAQ з таргетної терапії при раку легень в Південній Кореї","kind":"content"},{"text":"Отримати безкоштовну консультацію","kind":"content"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}